Pruzanski, Mark
Mark Pruzanski is a physician and entrepreneur with more than 30 years of experience in the life sciences. Most recently he served as Chairman and Chief Executive Officer of Versanis Bio where he spearheaded the development of novel therapies for obesity and other cardiometabolic diseases until the company’s acquisition in 2023 by Eli Lilly and
![](https://abcuro.com/wp-content/uploads/mark_pruzanski_headshot.jpg)
Mark Pruzanski, MD
Chairman of the Board
![](https://abcuro.com/wp-content/uploads/mark_pruzanski_headshot.jpg)
Mark Pruzanski, MD
Chairman of the Board
Martin, Alex
Alex Martin brings over 30 years of experience building companies and closing transactions in the biopharmaceutical industry. He was most recently Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company which was acquired by Centessa Pharmaceuticals (CNTA), and previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA
![](https://abcuro.com/wp-content/uploads/alex_martin_headshot2.png)
Alex Martin
Chief Executive Officer
![](https://abcuro.com/wp-content/uploads/alex_martin_headshot2.png)
Alex Martin
Chief Executive Officer
Dybbs, Mike
Mike is currently a partner at Samsara BioCapital, where he has worked since March 2017. Prior to joining Samsara, Mike was a partner at New Leaf Venture Partners. Before New Leaf Venture Partners Mike was a principal at the Boston Consulting Group, where he consulted for biotech and pharma clients. Mike currently serves on the
![](https://abcuro.com/wp-content/uploads/Mike-Dybbs.png)
Mike Dybbs, PHD
Partner, Samsara BioCapital
![](https://abcuro.com/wp-content/uploads/Mike-Dybbs.png)
Mike Dybbs, PHD
Partner, Samsara BioCapital
Knowles, Julius (Jay)
Jay Knowles joined Mass General Brigham Ventures in 2014 as a Partner. Previously, Jay was Chief Executive Officer of X-BODY Biosciences, which was acquired by Juno Therapeutics. Prior to X-BODY, he was at Novartis in charge of the Platforms team for Strategic Alliances, responsible for global technology and drug discovery collaborations. Jay was also President
![](https://abcuro.com/wp-content/uploads/JuliusKnowles_Partners.png)
Julius (Jay) Knowles
Partner, Mass General Brigham Ventures
![](https://abcuro.com/wp-content/uploads/JuliusKnowles_Partners.png)
Julius (Jay) Knowles
Partner, Mass General Brigham Ventures
Jay Knowles joined Mass General Brigham Ventures in 2014 as a Partner. Previously, Jay was Chief Executive Officer of X-BODY Biosciences, which was acquired by Juno Therapeutics. Prior to X-BODY, he was at Novartis in charge of the Platforms team for Strategic Alliances, responsible for global technology and drug discovery collaborations. Jay was also President of Novalar Pharmaceuticals, Vice President of Business Development at Novacea, and Director, R&D Planning at Vertex Pharmaceuticals. He represents Mass General Brigham Ventures on the boards of Apres Therapeutics, Keros Therapeutics, SwanBio Therapeutics, and Triplet Therapeutics. Jay earned his M.B.A in Finance from Wharton Business School, an M.Sc. in Chemistry from UC Berkeley, and a B.A. with Distinction in Chemistry from Carleton College.
Hafler, Jason P. , PhD
Jason P. Hafler is the Managing Director of Sanofi Ventures. Prior to joining Sanofi in 2014, Jason was the Director of Corporate Development at RaNA Therapeutics, a company co-founded by his previous firm Atlas Venture. While at Atlas, Jason was an Associate in the Life Sciences group. Previously, he was a Flagship Ventures Entrepreneurial Fellow,
![](https://abcuro.com/wp-content/uploads/jason_hafler_color.png)
Jason P. Hafler, PhD
Managing Director, Sanofi Ventures
![](https://abcuro.com/wp-content/uploads/jason_hafler_color.png)
Jason P. Hafler, PhD
Managing Director, Sanofi Ventures
Jason P. Hafler is the Managing Director of Sanofi Ventures. Prior to joining Sanofi in 2014, Jason was the Director of Corporate Development at RaNA Therapeutics, a company co-founded by his previous firm Atlas Venture. While at Atlas, Jason was an Associate in the Life Sciences group. Previously, he was a Flagship Ventures Entrepreneurial Fellow, and consulted for the technology transfer company at the University of Cambridge while performing his doctoral research. Before his time at Cambridge, Jason was an analyst at JSB Partners LP, an investment banking firm. Jason’s active investments include Abcuro, Amathus Therapeutics, Escient Pharmaceuticals, Expansion Therapeutics, Glycomine, Q32 Bio, ReCode Therapeutics, Rome Therapeutics and Navitor Pharmaceuticals. Jason graduated with honors from Bowdoin College and holds a Ph.D. from the University of Cambridge.
Kariv, Tomer
Tomer is the co-founder and Chief Executive Officer of Pontifax. He serves as an active board member of many of the funds’ portfolio companies, assuming a special responsibility for strategic planning. Among other positions, Tomer serves as the chairman at Eloxx Pharmaceuticals, board member in Cathworks, Keros Therapeutics, Ocon Healthcare, ARMGO and V-Wave. During the
![](https://abcuro.com/wp-content/uploads/tomer_kariv_headshot.png)
Tomer Kariv
Co-Founder and Chief Executive Officer, Pontifax
![](https://abcuro.com/wp-content/uploads/tomer_kariv_headshot.png)
Tomer Kariv
Co-Founder and Chief Executive Officer, Pontifax
Shah, Rajeev
Rajeev Shah has been a Managing Partner at RA Capital Management since 2004. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. He is also active in the firm’s outreach efforts, speaking frequently both at industry events and in classrooms. He previously worked as a
![](https://abcuro.com/wp-content/uploads/rajeev_shah_color.png)
Rajeev Shah
Managing Partner, RA Capital Management
![](https://abcuro.com/wp-content/uploads/rajeev_shah_color.png)
Rajeev Shah
Managing Partner, RA Capital Management
Deptula-Hicks, Darlene
Darlene Deptula-Hicks has served on the board of directors and as audit committee chair of Abcuro since July 2021. Darlene joined Aerami Therapeutics as Chief Financial Officer in October 2023, where she has been on the board of directors and chair of the audit committee since October 2021. Prior to Aerami, Darlene most recently served
![](https://abcuro.com/wp-content/uploads/Darlene-Deptula-Hicks.jpg)
Darlene Deptula-Hicks
Board of Directors & Audit Committee Chair
![](https://abcuro.com/wp-content/uploads/Darlene-Deptula-Hicks.jpg)
Darlene Deptula-Hicks
Board of Directors & Audit Committee Chair
Berger, Dietmar
Dietmar Berger is currently the Chief Medical Officer and Head of Global Development at Sanofi, where he oversees the clinical portfolio of Sanofi across all therapeutic areas. With over 20 years of experience in leadership positions across both large pharmaceutical companies as well as innovative biotech companies, Dr. Berger brings extensive expertise in clinical development
![](https://abcuro.com/wp-content/uploads/dietmar_berger_headshot.png)
Dietmar Berger, MD, PhD
Observer, Chief Medical Officer
and Head of Global Development at Sanofi
![](https://abcuro.com/wp-content/uploads/dietmar_berger_headshot.png)
Dietmar Berger, MD, PhD
Observer, Chief Medical Officer
and Head of Global Development at Sanofi
Dietmar Berger is currently the Chief Medical Officer and Head of Global Development at Sanofi, where he oversees the clinical portfolio of Sanofi across all therapeutic areas. With over 20 years of experience in leadership positions across both large pharmaceutical companies as well as innovative biotech companies, Dr. Berger brings extensive expertise in clinical development and advancing programs all the way to market approval to Abcuro. As a trained hematologist and oncologist, Dr. Berger has extensive experience in therapeutic areas of high relevance to Abcuro’s programs. Prior to Sanofi, he was Global Head of R&D at Atara Biotherapeutics, an off-the-shelf cell therapy company. Previously he held senior positions in clinical development at Amgen, Bayer and Genentech where he served as the Senior Vice President of Global Clinical Development, Hematology/Oncology. Dr. Berger holds an M.D. and Ph.D. from the Albert-Ludwigs University School of Medicine in Freiburg, Germany, where he still maintains an adjunct faculty position.
Xu, Yajun
Yajun Xu is currently president of Hongsen Investment Group. She also serves as Senior Advisor for Shangbay Capital, co-founder of Epimab, and board member and advisor on numerous biotech companies in U.S. and China. Previously, she was Senior Vice President of Corporate Development at Shangpharma, Executive Vice President of Biology and Pre-Clinical Service at Chempartner
![](https://abcuro.com/wp-content/uploads/Yajun_Xu_headshot.png)
Yajun Xu, PhD
Observer
President, Hongsen
![](https://abcuro.com/wp-content/uploads/Yajun_Xu_headshot.png)
Yajun Xu, PhD
Observer
President, Hongsen
Yajun Xu is currently president of Hongsen Investment Group. She also serves as Senior Advisor for Shangbay Capital, co-founder of Epimab, and board member and advisor on numerous biotech companies in U.S. and China. Previously, she was Senior Vice President of Corporate Development at Shangpharma, Executive Vice President of Biology and Pre-Clinical Service at Chempartner in Shanghai, China. Prior to Joining Shangpharma, Yajun was Director of Inflammation at Millennium Pharmaceuticals and Senior Scientist at BASF Bioresearch (now AbbVie Bioresearch). She received her Ph.D. in Biochemistry at Brandeis University and postdoctoral training at Harvard School of Public Health.
Ming Fang
Ming Fang is a Managing Director at Redmile Group, LLC, a healthcare-focused investment firm. Prior to joining Redmile in 2016, Ming worked in the healthcare space as an investor at Safeguard Scientifics, a consultant at McKinsey & Company and ZS Associates, and an operator at Gilead Sciences. He received a B.A. in Computer Science from
![](https://abcuro.com/wp-content/uploads/ming_fang_headshot2.jpg)
Ming Fang
Observer
Managing Director, Redmile Group
![](https://abcuro.com/wp-content/uploads/ming_fang_headshot2.jpg)
Ming Fang
Observer
Managing Director, Redmile Group
Cashdan, Jonah
Jonah Cashdan joined Bain Capital Life Sciences in 2018. Prior to joining Bain Capital, he worked at J.P. Morgan in their healthcare investment banking group, evaluating and executing strategic alternatives including M&A and debt/equity financings for clients across the pharmaceutical, biotech and medtech sectors. Prior to joining J.P. Morgan, Jonah studied synaptic physiology and sensory system
![](https://abcuro.com/wp-content/uploads/jonah_cashdan.png)
Jonah Cashdan
Observer
Principal, Bain Capital Life Sciences
![](https://abcuro.com/wp-content/uploads/jonah_cashdan.png)
Jonah Cashdan
Observer
Principal, Bain Capital Life Sciences